The €900M Wager on Weight-Loss Drugs

CordenPharma launches a €900M three-year push to expand peptide manufacturing, chasing €1B in revenue by 2028

11 Jun 2026

CordenPharma has unveiled a €900 million, three-year investment programme to expand peptide manufacturing capacity across the US and Europe. The announcement, made on 20 May 2026, positions the contract drug manufacturer at the centre of one of the fastest-growing segments of the global medicines market. Demand for GLP-1 therapies, widely prescribed for diabetes and obesity, has outpaced production capacity industry-wide. Suppliers are feeling the pressure.

Plans include a new facility at an undisclosed European location, plus targeted upgrades at existing sites. Multiple long-term customer contracts have already been signed, giving the build-out a firm commercial footing before a single brick is laid.

Reaching €1 billion in peptide revenue by 2028 is the stated target. Getting there within roughly two years demands disciplined execution, but the secured contracts suggest customer confidence is solid. Investors will track construction milestones closely.

For pharmaceutical companies developing next-generation GLP-1 drugs, reliable manufacturing partnerships have long been a bottleneck, limiting how quickly new treatments reach patients. Broad investment at this scale helps de-risk the pipeline for drug developers and, ultimately, improves access for patients who depend on these medications. That is not a small thing.

Analysts project continued market growth well into the next decade. By committing this level of capital now, CordenPharma is placing a clear strategic bet on sustained demand, and if execution matches ambition, the company could become an indispensable partner in treating metabolic disease.